Healthcare stocks are holding on to very small gains today with
the NYSE Healthcare Sector Index advancing less than 0.1% while
shares of healthcare companies in the S&P 500 are up 0.2% as a
In company news, Cell Therapeutics Inc. (
) is up more than 19% in late trade, climbing as high as $1.38
today after saying it sold 15,000 shares of its Series 18
convertible preferred stock directly to Quogue Capital and an
affiliate of Perceptive Advisors in a registered direct
The deal, which was conducted without an underwriter or
placement agent, generated about $14.8 million in net proceeds
after offering expenses were deducted. The new funds will support
ongoing Phase III testing of its pacritinib drug candidate to treat
certain types of leukemia and lymphoma as well as commercialization
of its Pixuvri chemotherapy for non-Hodgkin B-Cell lymphoma in
In other sector news,
(+) NVAX, Said Genocea Biosciences, its partner developing a
treatment for moderate-to-severe herpes simplex virus type 2
infections, today published positive,interim topline data from
Phase I/IIA testing of its GEN-003 compound.
(-) NSPH, Prices its public sale of 15 million shares at $1.75
apiece, expected to generate $24.1 mln in net proceeds.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.